 SAN DIEGO, May 12, 2021 PRNewswire -- Viracta Therapeutics, Inc. Nasdaq: VIRX Viracta or the Company, a precision oncology company targeting virus-associated malignancies, today announced financial results for the first quarter of 2021 and provided a clinical and corporate update. Viracta has emerged from our first quarter as a publicly traded company well-positioned to make a significant impact on patients and create meaningful value for our shareholders. 